- Home
- APRE
as 11-21-2024 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 21.3M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 13.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $8.85 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,310,839 | Revenue Growth: | 130.31% |
| Revenue Growth (this year): | 116.72% | Revenue Growth (next year): | -23.34% |
Stock Insider Trading Activity of Aprea Therapeutics Inc. Common stock (APRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gilad Oren | APRE | President/CEO | Oct 23 '24 | Buy | $3.92 | 500 | $1,957.50 | 333,395 | |
| Duey Marc | APRE | Director | Oct 18 '24 | Sell | $4.58 | 6,462 | $29,583.04 | 233,651 | |
| Duey Marc | APRE | Director | Oct 16 '24 | Buy | $4.39 | 30,000 | $131,700.00 | 240,113 | |
| Gilad Oren | APRE | President/CEO | Oct 15 '24 | Buy | $2.90 | 250 | $725.00 | 333,395 | |
| Duey Marc | APRE | Director | Oct 14 '24 | Buy | $2.58 | 190 | $490.20 | 240,113 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Oct 11 '24 | Buy | $2.46 | 50 | $123.19 | 19,368 | |
| Seizinger Bernd R. | APRE | Director | Oct 11 '24 | Buy | $2.68 | 10,000 | $26,800.00 | 44,730 | |
| Gilad Oren | APRE | President/CEO | Oct 10 '24 | Buy | $2.57 | 1,150 | $2,971.00 | 333,395 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Oct 10 '24 | Buy | $2.61 | 450 | $1,174.50 | 19,368 |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Simply Wall St.
12 days ago
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
15 days ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
15 days ago
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
15 days ago
Pacira (PCRX) Q3 Earnings Beat Estimates
TipRanks
a month ago
Aprea Therapeutics presents preliminary results on APR-1051
Simply Wall St.
a month ago
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
GlobeNewswire
a month ago
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.